Sai Life Sciences Ltd
Sai Life Sciences Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Sai Life Sciences expects a revenue CAGR of 15% to 20% from the current run rate (~INR 2,200 crores). Sai Life Sciences projects revenue CAGR of 15% to 20% over the next few years.
From Sai Life Sciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Sai Life Sciences expects a revenue CAGR of 15% to 20% from the current run rate (~INR 2,200 crores).
- Growth in the short term will likely be driven by pharma clients, with biotech contributions expected to return to a balanced 50/50 mix long-term.
- CDMO segment showed strong 30%+ growth in FY26; growth outlook for FY27 and FY28 remains strong.
- Increased capex (~INR 1,100-1,300 crores) focused on capacity expansion (75%) and capability/technology (25%) to support volume growth.
- Revenue visibility has improved through long-term collaborations and added large pharma customers.
- Long-term volume growth will be enabled by expanding discovery, development, and commercial manufacturing capabilities.
- Biotech funding recovery and strategic pharma outsourcing expected to support sustained growth.
- Expect a stronger second half in FY27, guided by phasing of new capacity and commercial product ramp-up.
Profitability & Margins
See what Sai Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 capex guidance: INR 1,100 crores to INR 1,300 crores, funded via internal accruals and debt.
- Capex split: 75% towards capacity expansion (including 700 KL to 1,150 KL plant expansion and doubling process R&D capacity), 25% towards capability building and AI/digital technology.
- Brownfield expansions expected to take 12-18 months; greenfield sites may take 24-30 months.
- Peptide and ADC development capabilities are part of the current capex.
- Investments driven by clear demand visibility and strategic conversations with large pharma clients.
- AI/digital transformation investment includes intangible software/tools aiming to enhance productivity and data integration.
- Capex for new site expected to start late FY27 or early FY28.
- Capex approach is science-led, emphasizing flexibility and high long-term returns rather than capacity-heavy expansion.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the exact current or expected order book or pending orders in terms of value or volume.
- However, it indicates strong visibility and confidence into FY27 growth based on customer conversations.
- The company has seen increased late-stage and mid-stage development outsourcing from large pharma, enhancing pipeline visibility.
- Customers are providing better visibility of their pipelines, indicating more programs likely to translate into commercial manufacturing within 12-15 months.
- The company has added multiple new commercial molecules and Phase III/pre-registration molecules, suggesting a healthy and expanding order pipeline.
- Integrated CDMO and CRO engagements with large pharma and biotech customers are increasing, supporting a robust demand outlook.
- Overall, while exact order book figures are not stated, the company expresses optimism based on long-term strategic partnerships and expanding capacity.
Sai Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹602 Cr, net profit ₹104 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Sai Life Sciences Ltd Q4 FY26 results?
Sai Life Sciences expects a revenue CAGR of 15% to 20% from the current run rate (~INR 2,200 crores). Sai Life Sciences projects revenue CAGR of 15% to 20% over the next few years.
What is Sai Life Sciences Ltd share price analysis?
Sai Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 83.4 with a market cap of ₹29,600 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Life Sciences Ltd planning capital expenditure?
FY27 capex guidance: INR 1,100 crores to INR 1,300 crores, funded via internal accruals and debt.
Keep Sai Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.